Kevin Sidow - Jul 22, 2025 Form 3 Insider Report for CARLSMED, INC. (CARL)

Role
Director
Signature
/s/ Leonard Greenstein, as attorney-in-fact for Kevin Sidow
Stock symbol
CARL
Transactions as of
Jul 22, 2025
Transactions value $
$0
Form type
3
Date filed
7/22/2025, 05:30 PM
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Sidow Kevin Director C/O CARLSMED, INC., 1800 ASTON AVE., SUITE 100, CARLSBAD /s/ Leonard Greenstein, as attorney-in-fact for Kevin Sidow 2025-07-22 0001416947

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CARL Series B Preferred Stock Jul 22, 2025 Common Stock 28.9K Direct F1
holding CARL Stock Option (Right to Buy) Jul 22, 2025 Common Stock 51.6K $0.33 Direct F2, F3, F6
holding CARL Stock Option (Right to Buy) Jul 22, 2025 Common Stock 44.8K $2.12 Direct F2, F4, F6
holding CARL Stock Option (Right to Buy) Jul 22, 2025 Common Stock 7.2K $5.91 Direct F2, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 28,900 shares of Series B Preferred Stock issued to the Reporting Person on April 18, 2022. Each share of Series B Preferred Stock is convertible into one share of the Issuer's common stock immediately prior to the closing of the Issuer's initial public offering. These shares are reported after giving effect to the 1-to-5.58 reverse split of the Issuer's common and preferred stock, effected on July 10, 2025 (the "Reverse Split"). These shares are reported on an as-converted 1-to-1 basis and have no expiration date.
F2 These options are reported after giving effect to the Reverse Split of the Issuer's common stock.
F3 Includes 51,638 fully vested and exercisable options convertible into approximately 51,638 shares of the Issuer's common stock.
F4 Includes 13,067 fully vested and exercisable options convertible into approximately 13,067 shares of the Issuer's common stock, and 31,735 unvested stock options convertible into approximately 31,735 shares of the Issuer's common stock. These options began to vest on May 1, 2024, subject to a one-year cliff, and will be fully vested on May 1, 2028.
F5 Includes 7,196 unvested stock options convertible into approximately 7,196 shares of the Issuer's common stock which began to vest on December 31, 2024, subject to a one-year cliff, and will be fully vested on December 31, 2028.
F6 The exercise price has been adjusted to reflect the Reverse Split.